The investment objective of the scheme is to provide returns, before expenses, that are in line with the performance of Nifty MidSmall Healthcare Index (TRI), subject to tracking error.
Expert-managed portfolios tailored to your financial goals and risk appetite.
| Index Funds | 1M | 3M | 6M | 9M | 1Y | 2Y | 3Y | 4Y | 5Y | 10Y | ALL |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Fund returns | -7.21% | -4.04% | 9.78% | 13.04% | 9.37% | 6.64% | N/A | N/A | N/A | N/A | 14.91% |
| Category returns | -3.49% | -4.55% | -2.01% | -3.44% | -4% | -2.79% | 10.35% | 12.84% | 9.89% | 11.18% | N/A |
| Absolute returns | -7.21% | -4.04% | 9.78% | 13.04% | 9.37% | 13.74% | N/A | N/A | N/A | N/A | 41.18% |
| Rank within category | 212/216 | 59/207 | 10/199 | 7/193 | 9/184 | 5/116 | N/A | N/A | N/A | N/A | N/A |
| Index Funds | 2024 | 2025 | 2026 |
|---|---|---|---|
| Yearly returns | N/A | -1.53% | 10.72% |
| Q1 returns | N/A | -7.72% | -5.13% |
| Q2 returns | N/A | 6.1% | 20.02% |
| Q3 returns | 18.11% | -0.85% | 1.48% |
| Q4 returns | 4.31% | 1.43% | -4.18% |
0.25% on or before 15D, Nil after 15D
| Alpha | -0.106501 |
| Beta | 0.9961 |
| Sharpe Ratio | 0.232873 |
| Sortino Ratio | 0.480229 |
| R-Squared | 0.9963 |
| Tracking Error | 0.0868 |
| Downside Risk | 17.3304 |
| Std. Deviation (Annualised) | 15.1275 |
| Index Funds | 1M | 3M | 6M | 9M | 1Y | 3Y | 5Y | 10Y | ALL | Fund Size (Cr) | Exp. Ratio | Sharpe | Risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICICI Prudential NASDAQ 100 Index Fund - Growth | -1.52% | 1.37% | 12.73% | 20.33% | 27.46% | 30.85% | 18.72% | N/A | 18.87% | 3,738.17 | 1.06 | 0.39 | Very High |
| Motilal Oswal S&P 500 Index Fund - Regular Plan - Growth | -0.5% | 1.6% | 10.19% | 15.5% | 24.15% | 26.62% | 16.54% | N/A | 19.94% | 4,584.30 | 1.04 | 0.44 | Very High |
| ICICI Prudential Nifty Pharma Index Fund - Regular Plan - Growth | -4.18% | -0.29% | 13.6% | 15.38% | 14.48% | 18.13% | N/A | N/A | 18.71% | 163.10 | 1.18 | 0.29 | Very High |
| UTI Nifty 500 Value 50 Index Fund - Regular Plan - Growth | -4.93% | -6.29% | -9.73% | -4.85% | 2.97% | 18.1% | N/A | N/A | 23.08% | 838.01 | 1.21 | 0.21 | Very High |
| Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund - Regular Plan - Growth | -4.3% | -1.59% | 11.56% | 11.09% | 13.2% | 17.83% | 12.7% | N/A | 14.93% | 191.85 | 1.10 | 0.32 | Very High |
| Motilal Oswal BSE Enhanced Value Index Fund - Regular Plan - Growth | -3.42% | -6.2% | -9.67% | -9.99% | -0.86% | 17.49% | N/A | N/A | 24.9% | 2,131.66 | 1.12 | 0.19 | Very High |
| Aditya Birla Sun Life Nifty Smallcap 50 Index Fund - Regular Plan - Growth | -4.83% | -1.02% | 10.76% | 12.27% | 8.48% | 15.62% | 10.2% | N/A | 15.72% | 364.19 | 1.11 | 0.18 | Very High |
| Kotak Nifty Smallcap 50 Index Fund - Regular Plan - Growth | -5.01% | -1.19% | 10.63% | 11.86% | 8.08% | 15.42% | N/A | N/A | 24.48% | 259.53 | 0.92 | 0.18 | Very High |
| ICICI Prudential Nifty Auto Index Fund - Regular Plan - Growth | -5.75% | -5.5% | -2.85% | -7.06% | -5.92% | 15.29% | N/A | N/A | 19.15% | 234.49 | 0.95 | 0.18 | Very High |
| Tata Nifty MidSmall Healthcare Index Fund - Regular Plan - Growth Current | -7.21% | -4.04% | 9.78% | 13.04% | 9.37% | N/A | N/A | N/A | 14.91% | 220.69 | 1.12 | 0.23 | Very High |
| Name | Sector | Instrument | Assets % |
|---|---|---|---|
| Laurus Labs Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 11.84% |
| Lupin Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 7.57% |
| Aurobindo Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 7.09% |
| Fortis Healthcare Ltd. | Healthcare Services | Domestic Equities | 6.16% |
| Glenmark Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 5.40% |
| Alkem Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.78% |
| Mankind Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.36% |
| Ipca Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.11% |
| Biocon Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.96% |
| Gland Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.55% |
| Sai Life Sciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.24% |
| Krishna Institute of Medical Sciences Ltd | Healthcare Services | Domestic Equities | 3.06% |
| Aster DM Quality Care Ltd. | Healthcare Services | Domestic Equities | 2.86% |
| Neuland Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.83% |
| Wockhardt Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.68% |
| Acutaas Chemicals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.61% |
| Ajanta Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.53% |
| Dr. Lal Pathlabs Ltd. | Healthcare Services | Domestic Equities | 2.38% |
| Abbott India Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.17% |
| Piramal Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.97% |
| Granules India Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.92% |
| Narayana Hrudayalaya Ltd. | Healthcare Services | Domestic Equities | 1.90% |
| Global Health Ltd. | Healthcare Services | Domestic Equities | 1.86% |
| Onesource Specialty Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.84% |
| Glaxosmithkline Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.76% |
| Anthem Biosciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.42% |
| Natco Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.14% |
| Cohance Lifesciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.11% |
| Syngene International Ltd. | Healthcare Services | Domestic Equities | 1.06% |
| Poly Medicure Ltd. | Healthcare Equipment & Supplies | Domestic Equities | 0.98% |
| I) REPO | Cash & Cash Equivalents and Net Assets | 0.13% | |
| NET CURRENT LIABILITIES | Cash & Cash Equivalents and Net Assets | -0.24% | |
| Total | 100.00% | ||
Mr. Rakesh Prajapati is Assistant Fund Manager for Index Funds. He joined Tata Asset Management in June 2023 as a Senior Manager - Derivatives Dealer. He brings extensive experience in derivatives trading, having previously worked with ICICI Securities Ltd, Edelweiss Securities Ltd, and IDFC Securities Ltd, where he held key roles on the derivatives dealing desk. With a strong background in market analysis and risk management, Rakesh plays a crucial role in optimizing derivative strategies. He holds a B.Com degree from Mumbai University and brings a deep understanding of financial markets to his role.
Mr. Nitin Sharma joined Tata Asset Management in March 2025 as an Investment Dealer. He brings strong expertise in equity and ETF trading, gained from his previous roles at Share India Securities Ltd and Sharekhan Ltd, where he was part of their equity and ETF dealing teams. He holds a master's in financial management from Mumbai University and has a deep understanding of financial markets. From July 2025, he has also taken on the additional responsibility of Fund Manager - Index Funds.
Get personalized portfolio management services designed to grow and protect your wealth.
ChatGPT
Claude
Perplexity
